Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials

[1]  G. Úrrutia,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. , 2021, Revista espanola de cardiologia.

[2]  S. Atkin,et al.  The Effect of Free Androgen Index on the Quality of Life of Women With Polycystic Ovary Syndrome: A Cross-Sectional Study , 2021, Frontiers in Physiology.

[3]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[4]  Lili Zhou,et al.  The role of androgen and its related signals in PCOS , 2020, Journal of cellular and molecular medicine.

[5]  L. Thabane,et al.  Efficacy of Treatments for Polycystic Ovarian Syndrome Management in Adolescents , 2020, Journal of the Endocrine Society.

[6]  C. Yin,et al.  Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome , 2020, The Journal of Steroid Biochemistry and Molecular Biology.

[7]  Huaien Bu,et al.  The Effect of Metformin on Polycystic Ovary Syndrome in Overweight Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2020, International journal of endocrinology.

[8]  L. Moran,et al.  Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. , 2020, The Cochrane database of systematic reviews.

[9]  Z. Saadia.  Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women , 2020, Medical archives.

[10]  S. Atkin,et al.  miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review. , 2020, Life sciences.

[11]  R. Smolarczyk,et al.  Hormonal Effects on Hair Follicles , 2020, International journal of molecular sciences.

[12]  S. Atkin,et al.  A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome , 2020, Therapeutic advances in endocrinology and metabolism.

[13]  D. Khalili,et al.  A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. , 2020, Human reproduction.

[14]  L. Lerman,et al.  Effect of Metformin on Microvascular Endothelial Function in Polycystic Ovary Syndrome. , 2019, Mayo Clinic proceedings.

[15]  Wei Huang,et al.  Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. , 2019, Fertility and sterility.

[16]  B. Mol,et al.  Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta‐analyses , 2019, Clinical endocrinology.

[17]  N. Brown,et al.  Sitagliptin decreases visceral fat and blood glucoses in women with polycystic ovarian syndrome. , 2019, The Journal of clinical endocrinology and metabolism.

[18]  J. Risteli,et al.  Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study. , 2019, Fertility and sterility.

[19]  A. Nagy,et al.  Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial. , 2019, Journal of gynecology obstetrics and human reproduction.

[20]  A. Dang,et al.  Association of Luteinizing hormone and LH receptor gene polymorphism with susceptibility of Polycystic ovary syndrome , 2019, Systems biology in reproductive medicine.

[21]  J. Levine,et al.  Hyperandrogenic origins of polycystic ovary syndrome – implications for pathophysiology and therapy , 2019, Expert review of endocrinology & metabolism.

[22]  J. Qiao,et al.  Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility , 2019, Human reproduction open.

[23]  K. Hari Kumar,et al.  A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome , 2018, Journal of family medicine and primary care.

[24]  Soumitra Das,et al.  Cabell's Blacklist: A New Way to Tackle Predatory Journals , 2018, Indian journal of psychological medicine.

[25]  W. Liu,et al.  Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment , 2018, BMC Endocrine Disorders.

[26]  W. Xu,et al.  Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome , 2017, Clinical endocrinology.

[27]  A. Janež,et al.  DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[28]  M. Elsersy.  Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial , 2017, The Journal of Obstetrics and Gynecology of India.

[29]  J. Holst,et al.  Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome , 2017, Endocrine connections.

[30]  A. Janež,et al.  Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial , 2017, BMC Endocrine Disorders.

[31]  M. Karimi-Zarchi,et al.  Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT , 2016, International journal of reproductive biomedicine.

[32]  M. Rezaei,et al.  Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome , 2016, Indian journal of endocrinology and metabolism.

[33]  D. Ehrmann,et al.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. , 2016, Endocrine reviews.

[34]  A. Janež,et al.  Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study , 2016, Experimental and therapeutic medicine.

[35]  S. Bhattacharya,et al.  Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome , 2016, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[36]  D. Glintborg,et al.  Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives. , 2015, Metabolism: clinical and experimental.

[37]  A. Janež,et al.  Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study , 2015, Journal of Ovarian Research.

[38]  S. Rattanasiri,et al.  Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: A randomized controlled trial , 2015, The journal of obstetrics and gynaecology research.

[39]  A. Ghaneei,et al.  Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia , 2015, Iranian journal of reproductive medicine.

[40]  Ali Bijani,et al.  Effect of Metformin and Flutamide on Anthropometric Indices and Laboratory Tests in Obese/Overweight PCOS Women under Hypocaloric Diet , 2014, Journal of reproduction & infertility.

[41]  Jessica Babineau,et al.  Product Review: Covidence (Systematic Review Software) , 2014 .

[42]  B. Richelsen,et al.  Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome , 2014, Journal of Endocrinological Investigation.

[43]  A. Hermann,et al.  Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. , 2014, The Journal of clinical endocrinology and metabolism.

[44]  C. Ateş,et al.  Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial , 2014, Archives of Gynecology and Obstetrics.

[45]  A. Janež,et al.  Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin , 2013, European journal of endocrinology.

[46]  A. Ruokonen,et al.  Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. , 2013, The Journal of clinical endocrinology and metabolism.

[47]  A. Lanzone,et al.  Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: A randomized study , 2013, Journal of Endocrinological Investigation.

[48]  U. Puistola,et al.  Metformin decreases serum 8-hydroxy-2'-deoxyguanosine levels in polycystic ovary syndrome. , 2013, Fertility and sterility.

[49]  E. Jude,et al.  Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome , 2013, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[50]  E. Diamanti-Kandarakis,et al.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. , 2012, Endocrine reviews.

[51]  E. Baracat,et al.  Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study , 2012, Clinics.

[52]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[53]  I. Anaforoglu,et al.  Higher metabolic risk with National Institutes of Health versus Rotterdam diagnostic criteria for polycystic ovarian syndrome in Turkish women. , 2011, Metabolic syndrome and related disorders.

[54]  J. Chan,et al.  The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome--a double-blind randomized placebo-controlled study. , 2011, Fertility and sterility.

[55]  N. Georgopoulos,et al.  The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia , 2011, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[56]  B. Yan,et al.  Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta‐analysis , 2011, Clinical endocrinology.

[57]  A. Badawy,et al.  Treatment options for polycystic ovary syndrome , 2011, International journal of women's health.

[58]  J. Frystyk,et al.  Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. , 2010, Fertility and sterility.

[59]  F. Ghaffarpasand,et al.  Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. , 2010, Fertility and sterility.

[60]  C. Tempfer,et al.  Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[61]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[62]  A. Lanzone,et al.  Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. , 2010, Fertility and sterility.

[63]  C. Roehrborn,et al.  Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. , 2010, Urology.

[64]  C. Taner,et al.  Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients , 2010, Archives of Gynecology and Obstetrics.

[65]  S. Carlsen,et al.  Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. , 2009, Human reproduction.

[66]  Ş. Çetinkalp,et al.  The Effects of Rosiglitazone, Metformin, and Estradiol-cyproterone Acetate on Lean Patients With Polycystic Ovary Syndrome , 2009 .

[67]  B. Keevil,et al.  Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome , 2009, Clinical endocrinology.

[68]  R. Norman,et al.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. , 2009, Fertility and sterility.

[69]  S. Mudaliar,et al.  Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. , 2009, The Journal of clinical endocrinology and metabolism.

[70]  R. Norman,et al.  Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. , 2009, Fertility and sterility.

[71]  A. Janež,et al.  Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. , 2008, European journal of endocrinology.

[72]  K. Elkind-Hirsch,et al.  Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. , 2008, The Journal of clinical endocrinology and metabolism.

[73]  A. Janež,et al.  Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. , 2008, European journal of endocrinology.

[74]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[75]  Abdur Rahman Khan,et al.  Comparison of metabolic effects of metformin and rosiglitazone in the management of polycystic ovary syndrome (PCOS): A prospective, parallel, randomized, open-label study , 2008 .

[76]  Jie Wu,et al.  Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome , 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[77]  F. Manguso,et al.  Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[78]  W. Dodson,et al.  The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. , 2007, American journal of obstetrics and gynecology.

[79]  J. Dziura,et al.  Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. , 2007, The Journal of clinical endocrinology and metabolism.

[80]  Antonio Maria Morselli-Labate,et al.  Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. , 2006, The Journal of clinical endocrinology and metabolism.

[81]  H. Beck-Nielsen,et al.  Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. , 2006, Fertility and sterility.

[82]  T. Wilkin,et al.  The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome—a randomised, double‐blind, placebo‐controlled trial , 2006, BJOG : an international journal of obstetrics and gynaecology.

[83]  A. Ruokonen,et al.  Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. , 2006, Human reproduction.

[84]  A. Duleba,et al.  Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. , 2006, Fertility and sterility.

[85]  T. Strowitzki,et al.  Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. , 2006, The Journal of clinical endocrinology and metabolism.

[86]  A. Hermann,et al.  Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[87]  R. M. Reis,et al.  Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. , 2005, Human reproduction.

[88]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[89]  L. Hernández,et al.  Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[90]  N. Çakır,et al.  The effects of rosiglitazone and metformin on menstrual cyclicityand hirsutism in polycystic ovary syndrome , 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[91]  K. Salvesen,et al.  Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. , 2004, Human reproduction.

[92]  C. De Geyter,et al.  Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[93]  K. Salvesen,et al.  Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin. , 2004, Human reproduction.

[94]  U. Pagotto,et al.  Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome , 2004, Clinical endocrinology.

[95]  A. Dunaif,et al.  Polycystic ovary syndrome: Syndrome XX? , 2003, Trends in Endocrinology & Metabolism.

[96]  N. Sattar,et al.  Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. , 2003, The Journal of clinical endocrinology and metabolism.

[97]  I. Vauhkonen,et al.  Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. , 2003, The Journal of clinical endocrinology and metabolism.

[98]  P. Spritzer,et al.  Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[99]  F. Durmuşoǧlu,et al.  Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. , 2002, Human reproduction.

[100]  H. Malkawi,et al.  The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. , 2002, Saudi medical journal.

[101]  A. Paoletti,et al.  The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome. , 2002, Fertility and sterility.

[102]  H. Zeyneloglu,et al.  Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. , 2002, Human reproduction.

[103]  V. de Leo,et al.  Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. , 2001, Human reproduction.

[104]  P. Ho,et al.  Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. , 2001, Human reproduction.

[105]  W. Evans,et al.  Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. , 2001, Fertility and sterility.

[106]  I. Vauhkonen,et al.  Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. , 2000, The Journal of clinical endocrinology and metabolism.

[107]  L. Falsetti,et al.  Comparison of finasteride versus flutamide in the treatment of hirsutism. , 1999, European journal of endocrinology.

[108]  L. Falsetti,et al.  Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. , 1997, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[109]  A. Murdoch,et al.  Treatment of hirsutism in polycystic ovary syndrome with bromocriptine , 1987, British journal of obstetrics and gynaecology.

[110]  P. Fossati,et al.  A Double Blind Controlled Study of the Hormonal and Clinical Effects of Bromocriptine in the Polycystic Ovary Syndrome , 1986 .

[111]  K. Elkind-Hirsch,et al.  Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study. , 2017, Fertility and sterility.

[112]  A. Janež,et al.  A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome , 2015, Hormones.

[113]  G. Chrousos,et al.  Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. , 2011, Fertility and sterility.

[114]  S. Zoungas,et al.  Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. , 2010, Fertility and sterility.

[115]  C. Taner,et al.  Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome , 2009, Archives of Gynecology and Obstetrics.

[116]  G. Bozkaya,et al.  The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). , 2009, Internal medicine.

[117]  E. Kilpatrick,et al.  The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. , 2009, The Journal of clinical endocrinology and metabolism.

[118]  D. Cibula,et al.  The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. , 2005, Human reproduction.

[119]  N. Sut,et al.  Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. , 2005, Human reproduction.

[120]  B. Fauser,et al.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.

[121]  E. Çalışkan,et al.  Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. , 2002, Fertility and sterility.